Curis Stock Earnings Reports

Curis provided a Q1 2026 business update highlighting clinical and financial progress. Clinically, the company is advancing emavusertib: the registrational TakeAim Lymphoma study in primary CNS lymphoma (PCNSL) remains on track with a planned substantial enrollment/data update in the first half of 2027; a proof-of-concept TakeAim CLL combination study (emavusertib + zanubrutinib) is expected to dose the initial 5 patients by mid-2026 with initial data anticipated in December 2026. Curis emphasized the rationale for a dual-blockade approach (TLR inhibition by emavusertib plus BTK inhibition) to deepen responses, achieve CR/MRD-negativity, and potentially enable time-limited treatment in CLL. Safety expectations: regulators asked for dose evaluation at 100 mg and 200 mg (Project Optimus), and management does not expect major safety differences between those doses based on prior higher-dose experience and existing combo data. Financially, Curis reported a Q1 net loss of $24.2M versus $10.6M year-ago, driven largely by fair value changes tied to the January 2026 PIPE financing. R&D expenses declined to $6.4M, G&A rose to $5.1M (PIPE-related costs). Cash and equivalents were $15M as of March 31, 2026; anticipated potential gross proceeds of up to $20.2M from exercise of Series B warrants contingent on dosing the fifth CLL patient should extend runway into the second half of 2027. The company is focused on generating clinical data before pursuing broader commercial partnerships or advancing an AML registrational program.